Psilocybin Science & News

Since January 1, 2026, the Czech Republic allows Czech Republic psilocybin therapy for patients with treatment-resistant depression. Psychiatrists can now prescribe synthetic psilocybin under strict clinical conditions. This makes Czechia the first EU member state with a full legal framework for medical psilocybin. In this article, you will learn how the law works, who qualifies, and what the latest science says.

In this article: In April 2026, the largest psychedelic brain study ever published appeared in Nature Medicine. Researchers from five countries scanned more than 500 brain sessions. They found that psilocybin, LSD, mescaline, DMT, and ayahuasca all do the same two things to the human brain — despite being completely different molecules.

Here is what they found, why it matters, and what it means for the future of magic mushroom research.

Imagine living with a body that shakes, a mood that sinks and medicines that help your muscles a little but do almost nothing for the sadness and anxiety. Now imagine a single treatment that lifts your mood, sharpens your thinking and improves your movement. That is exactly what researchers at the University of California San Francisco found when they gave psilocybin to Parkinson's patients for the first time.

In 2024, a South African court ruled that banning psilocybin for private adult use was unconstitutional. Now, in 2026, lawyers and healers are pushing even further — calling for legal access to psilocybin South Africa-wide for therapeutic purposes. Here is what is happening and why it matters.

A tobacco plant producing psychedelics — it sounds unlikely, but that is exactly what scientists at the Weizmann Institute of Science have achieved. By genetically engineering Nicotiana benthamiana, a wild tobacco relative, researchers made the plant grow five well-known natural psychedelics at the same time: psilocybin and psilocin from magic mushrooms, DMT from plants, and bufotenine and 5-MeO-DMT from the Sonoran Desert toad. Published in Science Advances on 31 March 2026, this is the first study to bring together all five biosynthetic pathways — from three different kingdoms of life — inside a single tobacco plant for psychedelic production.

However, this is more than a chemistry story. It is a strong signal that the tobacco plant — a genus best known for addiction and disease — may become one of the most important production tools for the next generation of psychedelic medicines.

Two studies published in early 2026 — one from Dartmouth University, one from the University of Padua — point to the same exciting idea: the healing effects of psilocybin may not need hallucinations to work.

This matters for millions of people who are curious about psilocybin therapy but afraid of losing control, seeing things, or entering a strange mental state. Science is now showing there may be another way.

Bryan Johnson took magic mushrooms — twice. His team tracked 249 health markers before and after each session. The Bryan Johnson psilocybin experiment is the most measured psychedelic self-test ever made public. Some results were very positive. One result shocked even his own team.